Tg Therapeuticscmn (TGTX) said before open Wednesday that it earned $0.73 per share in quarter three 2023.
On the revenue line, the company reported $165.8 million, beating estimates by $119.3 million.
In the same quarter a year ago, the company lost $0.26 per share on revenue of $94 thousand.
The stock is steady today at $7.73 after the report.
The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.
Wall Street Analysts had an average rating of Buy on the stock prior to the report.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Prior to the report, InvestorsObserver gave the stock an overall score of 63. Meanwhile, the average Wall Street analyst rated the stock a Buy.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
News Home
Tg Therapeuticscmn Steady Today At $7.73 After Earnings Beat
Mentioned in this article
